WHO Sounds Warning Over Acute Scarcity of Weight-Loss Injections
Under 10% of patients eligible to benefit from weight-loss injections such as Wegovy are able to get them, states the WHO as it releases its initial recommendations on the drugs.
Considering in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is calling for increased and just access to GLP-1 medication.
Per forecasts, in excess of 2,000,000,000 could be obese by 2030 if no action is taken.
"The latest guidelines recognises that obesity is a chronic disease that can be treated with comprehensive and ongoing treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and supply-chain constraints are significant barriers to widespread access to the jabs that can aid individuals in losing substantial weight, explains the body.
Weight-Loss Drug Scarcity
Even under the present most favorable outlook, the manufacturing of these medications could only cover approximately 100 million people – under 10% of the global need, per the WHO.
The advice encourages nations and manufacturers to widen availability, by approaches like voluntary licensing.
Exclusive production rights on semaglutide – the main component of a leading brand – is due to expire in multiple countries in 2026.
How Obesity Jabs Operate
These medications replicate a natural hormone to reduce digestion speed, reduce hunger and boost the sense of being full so people reduce food intake.
People commonly begin shedding pounds in the initial weeks of starting on the weekly injections.
Evidence indicates patients may see weight return within a year of stopping the medication, because their normal food cravings come back.
Being above a healthy weight increases your chance for developing diseases, such as type 2 diabetes, cardiovascular issues, stroke, and certain cancers.
Excess weight impacts individuals in every country and was associated with over three and a half million fatalities worldwide in 2024, per the WHO.
